BioSpace News Archive

Mission Therapeutics (“Mission”), a drug discovery and development company focused on protein homeostasis by selectively inhibiting deubiquitylating enzymes (DUBs), announces that CEO, Dr Anker Lundemose, will present at the upcoming J.P Morgan Healthcare Conference.

Burning Rock (NASDAQ/LSE: BNR), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that its OverC™ Multi-Cancer Detection Blood Test (MCDBT) has been granted Breakthrough Device Designation by the US Food and Drug Administration (FDA), which is the third of its kind globally.

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, SEHK : 02315) and Hansoh Pharmaceutical Group Company Limited (“Hansoh Pharma”, SEHK: 3692) today announced an antibody collaboration, assignment and exclusive license agreement.

ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA; “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of renal and inflammatory diseases, announces that two leading nephrologists have joined ZyVersa’s Renal Scientific Advisory Board.

Ludwig Enterprises,Inc., with its wholly owned subsidiary, Precision Genomics, Inc., a leading-edge innovator of inflammatory genetic biomarkers to diagnose and manage chronic diseases, is pleased to announce Institutional Review Board (IRB) approval of a study titled “Using Measurements of mRNA and Elisa-based Cytokine/Protein Indices to Evaluate Pre- and Post- Diagnosis and Treatment Response of Patients With Urothelial Carcinoma of the Bladder.”

The global cell and gene therapy market size was exhibited at USD 18.61 billion in 2022 and is expected to expand around USD 93.78 billion by 2030, poised to grow at a projected CAGR of 22.41% from 2022 to 2030.

The global personalized medicine market is predicted to garner around US$ 5.7 trillion by 2030 and it is expected to reach at a registered CAGR of 11.6% over the forecast period 2022 to 2030.

Cadence, Inc., a leading contract manufacturer of medical and drug delivery devices and specialty commercial products, announced that it has acquired Utitec, Inc., a manufacturer specializing in miniature, deep drawn medical device and commercial components.

Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced that management will present a company overview and participate in a Q&A session at the 41st Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2023 at 9:45 am PT at The Westin St. Francis in San Francisco.

Deciphera Pharmaceuticals, Inc. announced findings of a planned exploratory analysis of data from the INTRIGUE Phase 3 clinical study of QINLOCK using circulating tumor DNA from a subgroup of patients with gastrointestinal stromal tumor previously treated with imatinib who harbor mutations in KIT exon 11 and 17/18 only.